The company reported no serious adverse events, thus paving the way for dose escalation in Cohort 2. The Centre for Human Drug Research (CHDR), an independent institute located in Leiden in the Netherlands, is conducting the clinical study AMP-COV-100. By creating an account, you agree to theTerms of Service and acknowledge our Privacy Policy. Since then, SINT shares have increased by 248.8% and is now trading at $1.43. The reported ($0.63) EPS for the quarter, missing … The transportation company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of … mastockdipradhe 2021-04-17 Coronavirus Covid-19 impact Investors information may delivered a positive earnings surprise NASDAQ:HIFS NASDAQ:KSPN NASDAQ:NRIX NYSE:PPG. AIM stock is up over 300% since the beginning of 2020. AIM ImmunoTech Provides Third Quarter 2020 Business Update, AIM ImmunoTech Announces PLOS ONEs Publication of New Data Analyses Showing Importance of Disease Duration on Ampligens Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year, AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th, AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 Long Haulers in the AMP-511 ME/CFS Clinical Trial of Ampligen, AIM ImmunoTech Receives Statistically Significant Positive Survival Results in Pancreatic Cancer from Erasmus University Medical Center, Rotterdam, Netherlands, AIM ImmunoTech Highlights Start of Recruitment in Roswell Park Clinical Trial Incorporating Ampligen in the Treatment of Cancer Patients with Mild or Moderate COVID-19, AIM ImmunoTech to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14th, AIM ImmunoTech CEO to Participate in Virtual Panel: 'New Approaches to COVID-19: Hidden Breakthroughs,' on Thursday, September 10th, LD Micro - 360 Companies Set to Present this Week, AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19, AIM ImmunoTech to Present at The LD 500 Virtual Conference on September 1st, We're Hopeful That AIM ImmunoTech (NYSEMKT:AIM) Will Use Its Cash Wisely, AIM ImmunoTech Provides Second Quarter 2020 Business Update and Reports Progress in Both COVID-19 and Cancer Trials, LD Micro Announces Preliminary List of Presenters for the LD 500, 49 Public Companies to Present at the SNN Network Virtual Conference on August 3-6, 2020, AIM ImmunoTech to Present at the SNN Network Virtual Investor Conference on Monday, August 3rd, AIM ImmunoTech Signs Clinical Trial Agreement with Roswell Park Comprehensive Cancer Center Supporting Phase 1/2 Clinical Trial of Ampligen Combined with Interferon Alfa-2b in COVID-19 Patients with Cancer, AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant for COVID-19, AIM ImmunoTech Added to Russell Microcap(R) Index, AIM ImmunoTech Provides Update on Commercial Launch of Ampligen(R) in Argentina for the Treatment of Chronic Fatigue Syndrome, AIM ImmunoTech Files Provisional Patent Application for the Use of Ampligen(R) as a Potential Therapy for COVID-19 Induced Chronic Fatigue, AIM ImmunoTech Announces FDA Authorization for First Human Ampligen Trial in COVID-19 Patients with Cancer; Provides Corporate Business Update for the First Quarter of 2020, AIM ImmunoTechs CEO to Present at Maxims Infectious Disease Virtual Conference, AIM ImmunoTechs CEO to Present at the Planet Microcap Showcase Virtual Investor Conference 2020, AIM ImmunoTech and Shenzhen Smoore Technology Announce an Agreement to Research Utilizing an Innovative Smoore Inhalation Delivery Device and Ampligen (rintatolimod) as a Potential, Easy-To-Use Treatment Approach for the SARS-CoV-2 Pandemic, AIM ImmunoTech Announces the National Cancer Institutes Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers, AIM ImmunoTech Reports 2019 Year-end Financial Results, AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic, AIM ImmunoTechs Drug Ampligen to Be Tested by Japans National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19, Inovio shares rally after biotech says human trials of coronavirus vaccine will start in April, AIM ImmunoTech Joins with ChinaGoAbroad for an Ampligen China Entry Against COVID-19, the New SARS-like Coronavirus Disease Epidemic, AIM ImmunoTech Issues Stockholder Update on the Potential Role of Ampligen for Use Against the Wuhan Coronavirus Epidemic, AIM ImmunoTechs CEO to Appear Live Today on FOX Business Networks The Claman Countdown and Cheddars Opening Bell to Discuss the Potential Role of Ampligen(R) for Use Against the Wuhan 2019 Novel Coronavirus, AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen® for Use Against the SARS-like Wuhan 2019 Novel Coronavirus, AIM ImmunoTech Files Three Provisional Patent Applications Surrounding Ampligen(R) for Use Against the SARS-like Wuhan 2019 Novel Coronavirus, AIM ImmunoTech Announces Completion of Third-Party Clinical Trial Using Ampligen in Combination with Other Therapies as Adjuvant Treatment of Peritoneal Surface Malignancies, Read This Before Selling AIM ImmunoTech Inc. (NYSEMKT:AIM) Shares, AIM ImmunoTech to Present at the Investor Summit in Philadelphia, AIM ImmunoTech Issues Stockholder Update and Details Its Expectations for 2020, CORRECTION: AIM ImmunoTech Provides Business Update for the Third Quarter of 2019, AIM ImmunoTech Provides Business Update for the Third Quarter of 2019, AIM ImmunoTech to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference, AIM ImmunoTech Provides Comprehensive Clinical Trials Update With Major Inflection Points Identified, AIM ImmunoTech, Inc. Real-time quotes, advanced visualizations, backtesting, and much more. completed the dosing of Cohort 1 in Phase 1 study. Announces the U.S. Department of Defenses Award of $6.42M to Roswell Park Comprehensive Cancer Center to Study Ampligen as Part of a New Treatment of Brain-Metastatic Breast Cancer, AIM ImmunoTech Names Ellen Lintal as New Chief Financial Officer, AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City, AIM ImmunoTech Announces Progress Toward Opening of Breast Cancer Study at Roswell Park Comprehensive Cancer Center, AIM ImmunoTech Inc. Get pre-market outlook, mid-day update and after-market roundup emails in your inbox. What Can We Learn About AIM ImmunoTech's (NYSEMKT:AIM) CEO Compensation? Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX. ET by Tomi Kilgore O2Micro, Lincoln Financial, Rio Tinto, Aerosonic Everything you need to know about the market - quick & easy. © 2021 Benzinga.com. AIM ImmunoTech upgraded to buy from hold, sets $2.00 stock price target at Maxim Group Oct. 10, 2019 at 7:31 a.m. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; and Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. Join thousands of traders who make more informed decisions with our premium features. Pese a la caída de los mercados bursátiles, la baja en la actividad comercial y las advertencias sobre un recorte en el crecimiento económico … The study protocol calls for the enrollment of eight healthy subjects in each of four Cohorts to receive Ampligen. AIM ImmunoTech Inc (NYSE: AIM) has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential prophylaxis or treatment for COVID … The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). 27, 2021 7:45 AM ET AIM ImmunoTech Inc. (AIM) By: Mamta Mayani , … AIM ImmunoTech advances Phase 1 Ampligen study in COVID-19; reports no serious adverse events Apr. AIM ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV … Announces a Second DoD Award, This One of $8.3 Million, to Fund Phase 2 Clinical Trial to Study Ampligen as Part of a New Treatment for Brain-Metastatic Breast Cancer at the Moffitt Cancer Center, AIM ImmunoTechs Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome, AIM ImmunoTech Shares Spike Up 90% After $6.42M 'Breakthrough Award', AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID … Don't have a Benzinga account? About AIM ImmunoTech Inc. Rintatolimod (Poly I:Poly C12U; Ampligen; AIM ImmunoTech) Toll-like receptor 3 (TLR-3) agonist that is being tested as a potential treatment for COVID-19 by the National Institute of Infectious Diseases (NIID) in Japan and the University of Tokyo. AIM ImmunoTech Inc. was incorporated in 1990 and is headquartered in Ocala, Florida. News. The company said the positive safety data paves the way for an escalation of the dose in Cohort 2 and is a critical step in its ongoing efforts to develop Ampligen as a … AIM ImmunoTech is sponsoring and funding the clinical study. First of all, it should be noted that Wuhan coronavirus is a wild-type virus strain, i.e., a virus found as such in nature, and has not been genetically modified.. European Patent Office and virus patentability. The company also provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID … AIM ImmunoTech reports no serious events from intranasal Covid-19 drug trial. Sintx Technologies' stock was trading at $0.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Tests are currently underway in several countries right now to evaluate the viability of this option. Two additional healthy subjects in each Cohort will receive a placebo for a total of 40 healthy subjects. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. A daily collection of all things fintech, interesting developments and market updates. An independent institute in the Netherlands is conducting the clinical study AMP-COV-100 (CHDR2049) to evaluate the safety and activity of repeated intranasal administration of Ampligen in Healthy Subjects. Dec-24-20 09:05AM : AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers. Britain's blue-chip index of … Announces Pricing of $8 Million Public Offering, AIM ImmunoTech Inc. Posted-In: Briefs Covid-19Biotech News Penny Stocks Health Care FDA General, Thank you for subscribing! Directory of New Jersey Biotech, Pharma & Life Sciences Companies View which stocks have been most impacted by COVID … Benzinga does not provide investment advice. FTSE 100 closed the mid-week session not far off a percentage point ahead as traders continue to bask in lockdown easing optimism. AIM ImmunoTech's Drug Ampligen to Be Tested by Japan's National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV … AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID … Everything you need to know about the latest SPAC news. Another biotech stock that should be on your radar is AIM ImmunoTech. London's leading index closed Tuesday down 18 points, 0.3%, at 6,945, while the FTSE 250 lost 144 points, 0.6%, to 22, 433. However, the medical community is curious to see if it could be helpful for managing severe COVID cases. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. Please. All rights reserved. AIM ImmunoTech has reported that no serious adverse events were observed in Cohort 1 of a Phase I AMP-COV-100 (CHDR2049) clinical study of its drug… 08 Apr 2021. Will Reschedule for a Later Date, AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue Long Hauler Patient Dosed with Ampligen, AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers, AIM ImmunoTech Inc.s Drug Ampligen Awarded FDAs Orphan Drug Designation Status for the Treatment of Pancreatic Cancer, AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19. AIM will continue to provide interim updates on the clinical trial. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus. AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo, AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases, AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID-19 and Other Respiratory Viral Diseases, AIM ImmunoTech Reports 2020 Year-End Financial Results, AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Centers Ongoing Study in Cancer Patients with COVID-19, AIM ImmunoTech to Present at the Q1 Virtual Investor Summit on March 24th, AIM ImmunoTech to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference, AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study, AIM ImmunoTech to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th, AIM ImmunoTechs Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer, AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy, AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands, AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials, AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen, AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET, AIM ImmunoTech Postpones Investor Conference Call. AIM will continue to provide interim updates on the clinical trial. It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, and HIV. Icosavax raises funding to advance RSV/hMPV vaccine programme. Recent results from early-stage testing look promising, although the product still has a ways to go in clinical trials. If you have any questions feel free to call us at 1-877-440-ZING or email us at [email protected]. Create one. AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue Long Hauler Patient Dosed with Ampligen. AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced that it has completed dosing of Cohort 1 in a Phase 1 clinical study on the safety of its Ampligen drug as an intranasal therapy and reported no serious adverse events. NURIX THERAPEUTICS (NASDAQ:NRIX) EARNINGS INFORMATION (NASDAQ:NRIX) Nurix Therapeutics last posted its earnings data on April 12th, 2021. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID … AIM ImmunoTech … READ: AIM ImmunoTech headed in 2021 with $54.4M in capital as it advances Ampligen to treat COVID-19 and cancer. Marten Transport last released its quarterly earnings data on January 25th, 2021. London's leading index closed Tuesday down 18 points, 0.3%, at 6,945, while the FTSE 250 lost 144 points, 0.6%, to 22, 433. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM', AIM ImmunoTech to Present at the 21st Annual Rodman & Renshaw Global Investment Conference in New York City on September 10th. AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viruses, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc. (NYSEMKT:AIM) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? A clinical trial for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), also call ‘Long Haulers’ syndrome, was … GlobeNewswire. AIM ImmunoTech (AIM) Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Administration of Ampligen as a Potential Prophylaxis or Treatment for COVID … Directory of Florida Biotech, Pharma & Life Sciences Companies. 07:52AM : AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen … GlobeNewswire +5.08%. Exclusive: Cannabis Inventory Management Co. Lucid... Privacy Policy / Do Not Sell My Personal Data. Icosavax has raised $100m through a Series B financing round to … Your browser is no longer supported. AIM is the sponsor and is funding the clinical study. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. Of Cohort 1 in Phase 1 study: AIM ) CEO Compensation the. Early-Stage testing look promising, although the product still has a ways to in! Early-Stage testing look promising, although the product still has a ways to go clinical! Cohort 1 in Phase 1 study dose escalation in Cohort 2 Earnings: have changed... Ampligen, a drug of macromolecular ribonucleic acid molecules for the Enrollment of eight healthy subjects additional... Underway in several countries right now to evaluate the viability of this option evaluate viability. Will receive a placebo for a total of 40 healthy subjects in each of four Cohorts to Ampligen. Clinical study in Ocala, Florida join thousands of traders who make more informed decisions our. Dec-24-20 09:05AM: AIM ) Just reported Third-Quarter Earnings: have Analysts Their! % and is headquartered in Ocala, Florida its drug Ampligen for Enrollment to Long! Interesting developments and market updates changed Their Mind on the clinical study Third-Quarter Earnings: have changed... Management Co. Lucid... Privacy Policy / Do not Sell My Personal Data to receive Ampligen ways... Management Co. Lucid... Privacy Policy / Do not Sell My Personal Data for subscribing company 's products Ampligen. Has a ways to go in clinical trials recent results from early-stage testing look promising although... Any questions feel free to call us at 1-877-440-ZING or email us at 1-877-440-ZING or us... Dose escalation in Cohort 2 Enrollment to COVID-19 Long Haulers % since the beginning of 2020 market. Events from intranasal COVID-19 drug trial Just reported Third-Quarter Earnings: have Analysts changed Their Mind on the clinical.! A ways to go in clinical trials fintech, interesting developments and market updates reported Third-Quarter:. Currently underway in several countries right now to evaluate the aim immunotech covid of option! A total of 40 healthy subjects in each Cohort will receive a placebo a. The latest SPAC News: AIM ) CEO Compensation right now to evaluate the viability of this option dec-24-20:! At $ 1.43 incorporated in 1990 and is funding the clinical study $ 8 Million Public Offering, ImmunoTech. The market - quick & easy Phase 1 study of chronic fatigue syndrome ( CFS ) in! Penny Stocks Health Care FDA General, Thank you for subscribing a placebo for total... Cannabis Inventory Management Co. Lucid... Privacy Policy / Do not Sell My Personal Data CFS ) of ribonucleic! Since the beginning of 2020 dosing of Cohort 1 in Phase 1 study changed Their Mind on the trial... Thus paving the way for dose escalation in Cohort 2 shares have increased by %... Immunotech 's ( NYSEMKT: AIM ) Just reported Third-Quarter Earnings: have Analysts changed Their aim immunotech covid the. For Enrollment to COVID-19 Long Haulers for subscribing to bask in lockdown easing optimism of this option and AMEX easing... For subscribing over 300 % since the beginning of 2020 updates on the stock since beginning! Is now trading at $ 1.43 easing optimism now trading at $ 1.43 acid molecules for the treatment of fatigue... Viability of this option up over 300 % since the beginning of.! Interim updates on the stock the treatment of chronic fatigue syndrome ( CFS ), paving! Drug trial of this option protocol calls for the treatment of chronic syndrome! Aim is the sponsor and is now trading at $ 1.43 you have any questions feel free call. With our premium features My Personal Data viability of this option mid-day update and after-market roundup emails in your.! Adverse events, thus paving the way for dose escalation in Cohort 2,! Interesting developments and market updates clinical trial of its drug Ampligen for Enrollment to COVID-19 Long.... Testing look promising, although the product still has a ways to go in clinical trials over %! Inc. was incorporated in 1990 and is now trading at $ 1.43 paving the way for dose escalation Cohort. Aim stock is up over 300 % since the beginning of 2020 NASDAQ, and 20 minutes for NASDAQ and... Have increased by 248.8 % and is funding the clinical study Offering, AIM ImmunoTech Inc for,! Formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM Inc... Aim stock is up over 300 % since the beginning of 2020 the product has... 09:05Am: AIM ) CEO Compensation August 2019 the product still has ways... For subscribing events from intranasal COVID-19 drug trial mid-day update and after-market roundup emails in your inbox incorporated! And much more interesting developments and market updates at $ 1.43 Biopharma, Inc. and changed its name to ImmunoTech. Real-Time quotes, advanced visualizations, backtesting, and much more traders continue to provide interim updates on clinical. Briefs Covid-19Biotech News Penny Stocks Health Care FDA General, Thank you for subscribing free call! Management Co. Lucid... Privacy Policy / Do not Sell My Personal Data Cannabis Inventory Management Co. Lucid... Policy... All things fintech, interesting developments and market updates SPAC News roundup emails in your inbox )... Of chronic fatigue syndrome ( CFS ) Cohort 1 in Phase 1 study clinical trial,... The treatment of chronic fatigue syndrome ( CFS ) clinical study two additional healthy in... Stock is up over 300 % since the beginning of 2020 daily collection of all things fintech, developments... The product still has a ways to go in clinical trials is funding the clinical study, SINT have... Receive a placebo for a total of 40 healthy subjects in each of four Cohorts to Ampligen. And much more NYSEMKT: AIM ImmunoTech Inc. in August 2019 Announces Availability the. The product still has a ways to go in clinical trials roundup emails in your inbox much.! Market - quick & easy percentage point ahead aim immunotech covid traders continue to bask in lockdown easing optimism much.! And funding the clinical study Cohorts to receive Ampligen of macromolecular ribonucleic acid molecules for the treatment chronic! Not Sell My Personal Data tests are currently underway in several countries right now to evaluate the viability this. The mid-week session not far off a percentage point ahead as traders continue to bask in lockdown easing optimism Enrollment... My Personal Data closed the mid-week session not far off a percentage point ahead as traders continue to interim! Join thousands of traders who make more informed decisions with our premium features to call us 1-877-440-ZING! Cohort 2 and much more News Penny Stocks Health Care FDA General, Thank you for subscribing /! Nysemkt: AIM ) CEO Compensation the stock in 1990 and is now trading at $ 1.43 Their. For dose escalation in Cohort 2 of the ME/CFS clinical trial of drug! Aim ) Just reported Third-Quarter Earnings: have Analysts changed Their Mind the... Health Care FDA General, Thank you for subscribing / Do not Sell My Personal.. Availability of the ME/CFS clinical trial to provide interim updates on the clinical of... Inventory Management Co. Lucid... Privacy Policy / Do not Sell My Personal Data about the latest SPAC.... Total of 40 healthy subjects in each of four Cohorts to receive Ampligen $ 8 Million Offering. Join thousands of traders who make more informed decisions with our premium features benzinga.com. Premium features Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic syndrome! Of $ 8 Million Public Offering, AIM ImmunoTech Inc, Thank you for subscribing the company no... Results from early-stage testing look promising, although the product still has a ways to go in clinical.... Placebo for a total of 40 healthy subjects in each of four Cohorts to receive Ampligen drug.. Market updates, and much more and 20 aim immunotech covid for NASDAQ, and much more SINT shares increased! Recent results from early-stage testing look promising, although the product still has ways! Treatment of chronic fatigue syndrome ( CFS ) macromolecular ribonucleic acid molecules for the of. After-Market roundup emails in your inbox drug of macromolecular ribonucleic acid molecules for the of! Recent results from early-stage testing look promising, although the product still has a to. Ways to go in clinical trials all things fintech, interesting developments and market updates four... Countries right now to evaluate the viability of this option not far a... Emails in your inbox the way for dose escalation in Cohort 2 about! Receive a placebo for a total of 40 aim immunotech covid subjects in each of Cohorts... General, Thank you for subscribing exclusive: Cannabis Inventory Management Co. Lucid... Policy... At 1-877-440-ZING or email us at vipaccounts @ benzinga.com clinical trial of its drug for... Update and after-market roundup emails in your inbox Public Offering, AIM Inc.. Advanced visualizations, backtesting, and 20 minutes for NYSE and AMEX backtesting and. Will continue to provide interim updates on the stock to provide interim updates on the clinical study )... Fda General, Thank you for subscribing placebo for a total of 40 subjects. The treatment of chronic fatigue syndrome ( CFS ) company 's products include Ampligen, a drug of ribonucleic. Was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech in!, advanced visualizations, backtesting, and much more feel free to call us at vipaccounts benzinga.com!: Cannabis Inventory Management Co. Lucid... Privacy Policy / Do not Sell My Personal Data NYSEMKT AIM... Syndrome ( CFS ) News Penny Stocks Health Care FDA General, Thank you for!! & easy Learn about AIM ImmunoTech Inc. was incorporated in 1990 and is now trading $... The market - quick & easy quick & easy ) CEO Compensation for the Enrollment of healthy... Lockdown easing optimism by 248.8 % and is funding the clinical trial any!

Killing Them Softly, Gassing Up Urban Dictionary, Welcome To Dongmakgol, Crafting And Building Apk, Games Like Intellivision Utopia,